Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer

INTRODUCTION: The combination of a PD-L1 inhibitor plus carboplatin/cisplatin and etoposide (EC/EP) has become a new standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Combining concurrent palliative hypofractionated radiotherapy of the thorax (HFRT) and immunochemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chaoyuan, Zeng, Liang, Deng, Chao, Jiang, Wenjuan, Wang, Yapeng, Zhou, Yiguang, Liu, Li, Wang, Sisi, Zhou, Chunhua, Qiu, Zhenhua, Zeng, Fanxu, Wu, Fang, Weng, Jie, Liu, Xianling, Yang, Nong, Ma, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282832/
https://www.ncbi.nlm.nih.gov/pubmed/37350968
http://dx.doi.org/10.3389/fimmu.2023.1175960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282832/
https://www.ncbi.nlm.nih.gov/pubmed/37350968
http://dx.doi.org/10.3389/fimmu.2023.1175960

Ejemplares similares